Understanding patient outcomes in the real world

The pharma industry of today understands that good real-world patient outcomes can carry as much weight as robust regulatory data, so understanding drug use beyond the clinical trial setting is critical for success. Here, Kantar Health investigates the assumptions underlying drug decision-making by comparing opinions from attendees at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting with actual patient-reported data from its National Health and Wellness Survey (NHWS).

This exclusive white paper present the results of these survey questions alongside analysis based on the patient-reported data and raises some important issues around successfully factoring in real-world factors when making critical decisions around drug development and commercialization, including:

• Differences between diagnosed and real patient populations

• The impact of comorbidities on successful medical intervention

• How more convenient therapies impact health outcomes

• The critical role for real patient data in decision making

Click on the ‘Download the white paper’ button now to obtain your free copy.

For more information about Kantar Health visit www.kantarhealth.com or email nhws@kantarhealth.com for more information on its National Health and Wellness Survey (NHWS) data.